Clinical trial
Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress…
NCT00306540 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00306540 |
|---|---|
| Title | Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress Disorder |
| Official title | A Multicentre, Parallel Group, Randomised, Double Blind, Placebo Controlled Study of the Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress Disorder |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Post-Traumatic Stress Disorder |
| Intervention type | Drug |
| Interventions | Quetiapine Fumarate, quetiapine fumarate placebo |
| Enrollment | 90 |
| Start date | Dec 1, 2004 |
| Primary completion | Sep 1, 2007 |
| Completion | Aug 1, 2008 |
| First posted | Mar 24, 2006 |
| Last update posted | Dec 9, 2010 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: